An Open-label, Single-sequence, Drug-drug Interaction Study to Evaluate the Effect of Steady-state Carbamazepine on the Single-dose Pharmacokinetics of Erdafitinib Tablets in Healthy Adult Subjects
Latest Information Update: 31 Oct 2023
At a glance
- Drugs Carbamazepine (Primary) ; Erdafitinib (Primary)
- Indications Bladder cancer; Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 12 Sep 2023 Results (n=13) assessing drug-drug interaction (DDI)potential of erdaftinib when coadministered with multiple doses of carbamazepine presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 14 Jul 2022 Status changed from recruiting to completed.
- 19 May 2022 Planned End Date changed from 1 Oct 2022 to 1 Feb 2023.